Inflammatory bowel disease after liver transplantation: Risk factors for recurrence and de novo disease

American Journal of Transplantation

Volumn 6, Issue 6, 2006, Pages 1422-1429

  Verdonk, R C ^a,b   Dijkstra, G ^b   Haagsma, E B ^b   Shostrom, V K ^c   Van Den Berg, A P ^b   Kleibeuker, J H ^b   Langnas, A N ^a   Sudan, D L ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; MESALAZINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; VALGANCICLOVIR;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; COLON RESECTION; DISEASE SEVERITY; ENTERITIS; FEMALE; GRAFT REJECTION; HUMAN; INCIDENCE; INFECTION RISK; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OPERATION DURATION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VIRUS INFECTION;

EID: 33745813201     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01333.x     Document Type: Article

References (46)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429.
2. Gow PJ, Chapman RW. Liver transplantation for primary sclerosing cholangitis. Liver 2000; 20: 97-103.
3. McFarlane IG. Definition and classification of autoimmune hepatitis. Semin Liver Dis 2002; 22: 317-324.
4. Papatheodoridis GV, Hamilton M, Rolles K, Burroughs AK. Liver transplantation and inflammatory bowel disease. J Hepatol 1998; 28: 1070-1076.
5. Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983; 85: 713-717.
6. Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol 2005; 21: 293-299.
7. Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis 2005; 11: 62-72.
8. Befeler AS, Lissoos TW, Schiano TD et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998; 65: 393-396.
9. Dvorchik I, Subotin M, Demetris AJ et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 2002; 35: 380-384.
10. Haagsma EB, Van Den Berg AP, Kleibeuker JH, Slooff MJ, Dijkstra G. Inflammatory bowel disease after liver transplantation: The effect of different immunosuppressive regimens. Aliment Pharmacol Ther 2003; 18: 33-44.
11. Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43: 639-644.
12. Riley TR, Schoen RE, Lee RG, Rakela J. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol 1997; 92: 279-282.
13. Verdonk RC, Haagsma E, Van Den Berg AP et al. Inflammatory bowel disease after liver transplantation: A role for cytomegalovirus infection. Scand J Gastroenterol 2005 (in press).
14. Jungling B, Kindermann I, Moser C et al. Development of ulcerative colitis after heart transplantation during immunosuppressive therapy. Z Gastroenterol 2005; 43: 195-199.
15. Gavaler JS, Delemos B, Belle SH et al. Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Dig Dis Sci 1991; 36: 321-328.
16. van de Vrie W, de Man RA, van Buuren HR, Schouten WR, Tilanus HW, Metselaar HJ. Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2003; 15: 657-663.
17. Feagan BG. Maintenance therapy for inflammatory bowel disease. Am J Gastroenterol 2003; 98: S6-S17.
18. Lundqvist K, Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997; 40: 451-456.
19. Moayyeri A, Daryani NE, Bahrami H, Haghpanah B, Nayyer-Habibi A, Sadatsafavi M. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J Gastroenterol Hepatol 2005; 20: 366-370.
20. D'Haens G, Lemmens L, Geboes K et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-1329.
21. de Saussure P, Soravia C, Morel P, Hadengue A. Low-dose oral microemulsion ciclosporin for severe, refractory ulcerative colitis. Aliment Pharmacol Ther 2005; 22: 203-208.
22. Hogenauer C, Wenzl HH, Hinterleitner TA, Petritsch W. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 415-423.
23. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; 25CD004277.
24. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: A long-term experience. Eur J Gastroenterol Hepatol 2005; 17: 79-84.
25. Gonvers JJ, Juillerat P, Mottet C et al. Maintenance of remission in Crohn's disease. Digestion 2005; 71: 41-48.
26. Domenech E, Garcia-Planella E, Bernal I et al. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 2061-2065.
27. Egan LJ, Sandborn WJ. Advances in the treatment of Crohn's disease. Gastroenterology 2004; 126: 1574-1581.
28. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004; 126: 1582-1592.
29. Baan CC, van der Mast BJ, Klepper M et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005; 80: 110-117.
30. Demirkiran A, Kok A, Kwekkeboom J, Metselaar HJ, Tilanus HW, van der Laan LJ. Decrease of CD4+CD25+ T cells in peripheral blood after liver transplantation: association with immunosuppression. Transplant Proc 2005; 37: 1194-1196.
31. Shibutani S, Inoue F, Aramaki O et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation 2005; 79: 904-913.
32. Coombes JL, Robinson NJ, Maloy KJ, Uhlig HH, Powrie F. Regulatory T cells and intestinal homeostasis. Immunol Rev 2005; 204: 184-194.
33. Maul J, Loddenkemper C, Mundt P et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005; 128: 1868-1878.
34. Uhlig HH, Powrie F. The role of mucosal T lymphocytes in regulating intestinal inflammation. Springer Semin Immunopathol 2005; 27: 167-170.
35. Sandalova E, Wei CH, Masucci MG, Levitsky V. Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering. Proc Natl Acad Sci U S A 2004; 101: 3011-3016.
36. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002; 128: 255-266.
37. Takahashi K, Reynolds M, Ogawa N, Longo DL, Burdick J. Augmentation of T-cell apoptosis by immunosuppressive agents. Clin Transplant 2004; 18: 72-75.
38. Peppelenbosch MP, van Deventer SJ. T cell apoptosis and inflammatory bowel disease. Gut 2004; 53: 1556-1558.
39. Van Den Brande JM, Peppelenbosch MP, van Deventer SJ. Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann N Y Acad Sci 2002; 973: 166-180.
40. Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004; 10: 488-491.
41. Gabe SM, Bjarnason I, Tolou-Ghamari Z et al. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. Gastroenterology 1998; 115: 67-74.
42. de Maar EF, Kleibeuker JH, Boersma-van Ek W, The TH, van Son WJ. Increased intestinal permeability during cytomegalovirus infection in renal transplant recipients. Transpl Int 1996; 9: 576-580.
43. Koskinen PK, Lemstrom KB, Nieminen MS, Hayry PJ, Lautenschlager IT. Vascular cell adhesion molecule-1 (VCAM-1) is induced during cytomegalovirus infection in vascular structures of heart allografts. Transpl Int 1994; 7(Suppl 1): S363-S364.
44. Orvar K, Murray J, Carmen G, Conklin J. Cytomegalovirus infection associated with onset of inflammatory bowel disease. Dig Dis Sci 1993; 38: 2307-2310.
45. Rahbar A, Bostrom L, Lagerstedt U, Magnusson I, Soderberg-Naucler C, Sundqvist VA. Evidence of active cytomegalovirus infection and increased production of IL-6 in tissue specimens obtained from patients with inflammatory bowel diseases. Inflamm Bowel Dis 2003; 9: 154-161.
46. Jain A, Demetris AJ, Kashyap R et al. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl 2001; 7: 623-630.